Structure Therapeutics Inc. American Depositary Shares (GPCR · NASDAQ)

GPCR · MARKET VIEW

Market view · as of Sep 7, 2026

Revenue (TTM)
$0
0.0% YoY
EPS (latest q)
$-0.49
vs $-0.39 est · miss
52-wk position
36.9%
-49.5% vs 52w high · -10.9% 1mo

Price (last ~year)

Structure Therapeutics (GPCR) is advancing its oral GLP-1 candidate, aleniglipron, to Phase 3 development following Phase 2b results showing 16.2% weight loss. The clinical-stage biopharmaceutical company holds a $3.38 billion market capitalization with $272.6 million in cash and $6.2 million in debt as of June 30, 2026. Financial results for the second quarter reflect $0 revenue and a net loss of $106.2 million. Shares closed at $47.34, down 10.9% over the past month.

Valuation

Market cap
$3.38B
P/B
2.499
EV/EBITDA
-13.46
Beta
-1.521
Analyst target
$104.77

Quality & returns

Operating margin
0.0%
Profit margin
0.0%
ROE
-20.2%
ROA
-14.9%

Price movement

Last
$47.34
1-month
-10.9%
3-month
+14.0%
RSI (14)
26
vs SMA200
-12.9%
52-wk position
36.9% -49.5% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-06-30$0$-118.6M$-106.2M$-105.9M
2026-03-31$0$-89.6M$-76.2M$-74.8M
2025-12-31$0$24.0M$33.0M$33.6M
2025-09-30$0$-73.8M$-65.7M$-65.3M

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots